Phase
Condition
Scleroderma
Stress
Heart Disease
Treatment
N/AClinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Informed consent
PH diagnosed according to internation Guidelines: mPAP ≥ 25 mmHg along with a PAWP ≤15mmHg during right heart catheterization at the time of Initial diagnosis
PH class 1 (PAH) or 4 (CTEPH)
Stable condition, on the same medication for > 4 weeks
Patient live permanently at an altitude < 1000m asl.
Exclusion
Exclusion Criteria:
Resting PaO2 ≤7.3 kPA corresponding to the requirement of long-term oxygen therapy > 16hour daily (nocturnal oxygen therapy alone is allowed)
Severe daytime hypercapnia (pCO2 > 6.5 kPa)
Susceptibility to high altitude related diseases (AMS, HAPE, etc.) based on previousexperienced discomfort at altitudes.
Exposure to an altitude >1500m for ≥3 nights during the last 4 weeks before the studyparticipation
Residence > 1000m above sea level
Inability to follow the procedures of the study, e.g. due to language problems,psychological disorders, neurological or orthopedic problems with Walking disability
Women who are pregnant or breast feeding
Study Design
Study Description
Connect with a study center
Respiratory Clinic, University Hospital of Zurich
Zurich, 8091
SwitzerlandSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.